Efbemalenograstim Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Efbemalenograstim Alfa. Educational only — not medical advice.
Labeled uses
RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Source: FDA labeling via NIH DailyMed (set 290ed754…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.